Patents by Inventor Gad Getz

Gad Getz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230287510
    Abstract: As described below, the present invention features compositions, panels of biomarkers, and methods for characterizing chronic lymphocytic leukemia (CLL) for prognosis and selection of a subject for a treatment and/or inclusion in a clinical trial.
    Type: Application
    Filed: August 9, 2021
    Publication date: September 14, 2023
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Catherine J. WU, Gad GETZ, Binyamin A. KNISBACHER, Ziao LIN, Cynthia K. HAHN
  • Patent number: 11608533
    Abstract: The present disclosure relates to detecting microsatellite indels in cancer patients and those at high risk for cancer, and is useful for early detection of specific types of cancer and early onset of relapse. More particularly, the present disclosure relates to compositions, methods, and kits for classifying and treating neoplasia and tumors with microsatellite instability. The instant classifier identifies preferred therapeutic options, including combination therapies, for MSI tumor or cancer, and is particularly useful for patient stratification so that patients who would be treatable by immunotherapy drugs may be identified at a very low cost.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 21, 2023
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Yosef E. Maruvka, Gad Getz
  • Publication number: 20220282333
    Abstract: The present invention provides methods of predicting a patient's response to immunotherapy, in particular checkpoint blockade therapy, and provides for treatments. Disclosed herein are novel combinations of factors identified in tumors used to predict response and provide for treatments. Also, disclosed are methods of treatment that can shift a tumor to a responder phenotype.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Inventors: Samuel Freeman, Moshe Sade-Feldman, Nir Hacohen, Gad Getz, Matthew Meyerson
  • Publication number: 20210358574
    Abstract: The disclosure relates to methods for increasing the speed and efficiency of computational genomics. In particular, the disclosure relates to methods of scaling computational genomics by using one or more specialized architectures for highly parallelized computations, such as graphics processing units (GPUs), tensor processing units (TPUs), and field programmable gate arrays (FPGAs), and the like, to compute the computational genomics calculations.
    Type: Application
    Filed: October 15, 2019
    Publication date: November 18, 2021
    Applicants: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gad Getz, Amaro Taylor-Weiner, Francois Aguet
  • Patent number: 11002735
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: May 11, 2021
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz
  • Publication number: 20200407804
    Abstract: The present invention relates to methods of determining a cancer treatment prognosis for a subject in need thereof by evaluating epigenetic and genetic changes within a tumor sample from the subject. The present invention further provides methods of treating cancer in a subject by evaluating epigenetic and genetic changes within a tumor sample from the subject. In addition, the present invention provides methods of screening test agents to identify agents that decrease tumor cell plasticity.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 31, 2020
    Inventors: Mark K. Clement, Gad Getz, Dan-Avi Landau, Alexander Meissner, Catherine J. Wu
  • Publication number: 20200370133
    Abstract: The present invention features methods for characterizing mutational profiles in patients with bladder cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 26, 2020
    Applicants: The Broad Institute, Inc., The General Hospital Corporation, Baylor College of Medicine, The Brigham and Women?s Hospital, Inc., Northwestern University, The Johns Hopkins University, United States Government as represented by the U.S. Department of Veterans Affairs
    Inventors: Jaegil Kim, Gad Getz, Seth Paul Lerner, David Kwiatkowski, Joshua Meeks, Joaquim Bellmunt, David McConkey
  • Patent number: 10801070
    Abstract: The present invention relates to methods of determining a cancer treatment prognosis for a subject in need thereof by evaluating epigenetic and genetic changes within a tumor sample from the subject. The present invention further provides methods of treating cancer in a subject by evaluating epigenetic and genetic changes within a tumor sample from the subject. In addition, the present invention provides methods of screening test agents to identify agents that decrease tumor cell plasticity.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 13, 2020
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Mark Kendell Clement, Gad Getz, Dan-Avi Landau, Alexander Meissner, Catherine Ju-Ying Wu
  • Publication number: 20200225223
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 16, 2020
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. COHEN, Eytan DOMANY, Francisco Javier QUINTANA, Guy HED, Gad GETZ
  • Publication number: 20200147210
    Abstract: The subject matter disclosed herein is generally directed to CD8+ tumor infiltrating lymphocytes comprising gene signatures associated with response to immunotherapy treatment. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the gene signatures. Specifically, disclosed herein are gene signatures associated with response to checkpoint blockade therapy and immune cell subtypes characterized by said gene signatures. Further disclosed are methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs enriched for a specific subtype.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 14, 2020
    Inventors: Moshe SADE-FELDMAN, Karen YIZHAK, Gad GETZ, Nir HACOHEN
  • Publication number: 20190292602
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Bjoern Chapuy, Margaret Shipp, Chip Stewart, Andrew Dunford, Gad Getz
  • Publication number: 20190004045
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. COHEN, Eytan DOMANY, Francisco Javier QUINTANA, Guy HED, Gad GETZ
  • Patent number: 10082503
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 25, 2018
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz
  • Publication number: 20160326593
    Abstract: The present invention relates to methods of determining a cancer treatment prognosis for a subject in need thereof by evaluating epigenetic and genetic changes within a tumor sample from the subject. The present invention further provides methods of treating cancer in a subject by evaluating epigenetic and genetic changes within a tumor sample from the subject. In addition, the present invention provides methods of screening test agents to identify agents that decrease tumor cell plasticity.
    Type: Application
    Filed: November 24, 2014
    Publication date: November 10, 2016
    Inventors: Mark Kendell Clement, Gad GETZ, Dan-Avi LANDAU, Alexander MEISSNER, Catherine Ju-Ying WU
  • Publication number: 20160298185
    Abstract: A system and method for determining the exact pair of alleles corresponding to polymorphic genes from sequencing data and for using the polymorphic gene information in formulating an immunogenic composition. Reads from a sequencing data set mapping to the target polymorphic genes in a canonical reference genome sequence, and reads mapping within a defined threshold of the target gene sequence locations are extracted from the sequencing data set. Additionally, all reads from the set data set are matched against a probe reference set, and those reads that match with a high degree of similarity are extracted. Either one, or a union of both these sets of extracted reads are included in a final extracted set for further analysis. Ethnicity of the individual may be inferred based on the available sequencing data which may then serve as a basis for assigning prior probabilities to the allele variants. The extracted reads are aligned to a gene reference set of all known allele variants.
    Type: Application
    Filed: December 5, 2014
    Publication date: October 13, 2016
    Inventors: Sachet Ashok Shukla, Catherine Ju-Ying Wu, Gad Getz
  • Publication number: 20160004817
    Abstract: The invention relates to method for identifying significantly mutated genes includes determining a false discovery rate for each of the genes. The method may include estimating local mutation rates for the genes by converting each covariate to a centered and normalized score. The method may also include estimating a local background mutation rate for each of the genes, which may be estimated from silent and/or noncoding mutations of each of the genes itself. In some embodiments, the local background mutation rate may be estimated additionally from one or more neighbor genes in a covariate space. Related systems, techniques, and articles are also encompassed by the present invention.
    Type: Application
    Filed: September 15, 2015
    Publication date: January 7, 2016
    Inventors: Michael Lawrence, Gad Getz
  • Publication number: 20150197785
    Abstract: Methods and apparatus for inferring purity and ploidy from a sample of cells (e.g., a sample comprising cancer and normal cells) are described. Copy number per cell of interest (e.g., cancer cell) is determined by optimizing purity and ploidy for the sample based, at least in part, on relative copy number profile information. One or more likelihood fit scores are determined for each of a plurality of candidate solutions generated by the methods described herein. A solution is selected based, at least in part on the likelihood fit score(s) and the copy number per cancer cell is determined in accordance with the selected solution.
    Type: Application
    Filed: August 9, 2013
    Publication date: July 16, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Scott L. Carter, Gad Getz, Aaron McKenna, Matthew Meyerson
  • Publication number: 20150178445
    Abstract: A system, method, and computer program product for detecting variants from sequencing data. Aligned sequencing data can be provided and filters can be applied to the aligned sequencing data. The filtered data can be used as input, and a first classifier can be applied to determine if any alteration is present beyond an expected threshold due to a sequencing error and candidate variants can be identified. The identified candidate variants can be passed through additional filters to remove false positives. A somatic status of the filtered candidate variants can be determined using a second classifier. The related apparatus, systems, techniques and articles are also described.
    Type: Application
    Filed: February 27, 2015
    Publication date: June 25, 2015
    Inventors: Kristian CIBULSKIS, Gad GETZ, Michael LAWRENCE
  • Publication number: 20140364439
    Abstract: The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (CLL). Examples of these markers include drivers of CLL progression. The invention contemplates, inter alia, detecting the clonal, including subclonal, profile of CLL in a subject and the presence (or absence) of subclonal driver mutations, and utilizing this information in predicting disease progression, need, timing and/or nature of treatment regimen, and likelihood and frequency of relapse.
    Type: Application
    Filed: December 7, 2012
    Publication date: December 11, 2014
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Catherine J Wu, Gad Getz
  • Publication number: 20140200159
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 17, 2014
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz